

Anti-C5 [Eculizumab] Bulk Size Ab00296-25.0-BT

This antibody is a human IgG2/IgG4 hybrid.

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Isotype and Format: Human IgG2/4, Kappa

Clone Number: Eculizumab

Alternative Name(s) of Target: Complement Component 5; CPAMD4; Complement protein C5; h5G1.1

UniProt Accession Number of Target Protein: P01031

Published Application(s): Block, ELISA, EM Published Species Reactivity: Human

Immunogen: C5 is activated by C5 converatse into C5a, an anaphylatoxin, and C5b a component of the

membrane attack complex.

Specificity: Binds human C5 centred in the MG7 domain, at an epitope spanning Lys-879 to Arg-885 (Jore et al. 2016) Polymorphisms at Arg-885 correlate with drug resistance. Eculizumab demonstrates no appreciable species cross-reactivity. It is highly species specific. with no appreciable activity against chimpanzee, baboon, rhesus or cynomologous monkey, pig, rabbit, guinea pig, or rat complement **Application Notes:** This antibody inhibits activation of C5. The human Fab version (Ab00296-10.6) of this antibody was used by Jore et al. (2016, PMID: 27018802) to determine the binding site of this antibody to C5.

Antibody First Published in: Rother et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. PMID:17989688 **Note on publication:** Describes development and characterisation of Eculizumab.

Product Form

Size: 1 mg Purified antibody in bulk size. **Purification:** Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer

storage, aliquot and store at -20°C.

Concentration:

| 1 mg/ml. Important note – This product is for res | search use only. It is not intended for use in therapeutic or diagnostic |
|--|--|
| procedures for humans or animals. | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |